A5100387856- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Pharmaceutical studies and practices
- Schizophrenia research and treatment
- Antibiotics Pharmacokinetics and Efficacy
- Renal Transplantation Outcomes and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Central Venous Catheters and Hemodialysis
- Ion Transport and Channel Regulation
- Complement system in diseases
- Genetics and Neurodevelopmental Disorders
- Epigenetics and DNA Methylation
- Genomics and Rare Diseases
- Neonatal and fetal brain pathology
- Platelet Disorders and Treatments
- Cancer, Stress, Anesthesia, and Immune Response
- Mental Health and Psychiatry
- Pancreatic function and diabetes
- Vascular Malformations and Hemangiomas
- Genetic Associations and Epidemiology
- Drug Transport and Resistance Mechanisms
- Bipolar Disorder and Treatment
- Neuroscience and Neuropharmacology Research
- Pharmacogenetics and Drug Metabolism
- Electrolyte and hormonal disorders
Second Affiliated Hospital of Nanjing Medical University
2022-2024
Shandong University
2024
King's College London
2023
Harbin Medical University
2020
Third Affiliated Hospital of Harbin Medical University
2020
Augusta University
2016
Duke University
2016
Beijing Academy of Science and Technology
2013
Huashan Hospital
2010
Fudan University
2010
Choosing the appropriate antipsychotic drug (APD) treatment for patients with schizophrenia (SCZ) can be challenging, as response to APD is highly variable and difficult predict due lack of effective biomarkers. Previous studies have indicated association between genetic epigenetic factors, but no biomarkers been identified. Hence, further research imperative enhance precision medicine in SCZ treatment.Participants were recruited from two randomized trials. The discovery cohort was CAPOC...
This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy optimize a specific plasma reference range for PER in children. Another major aim was evaluate potential determinators concentration.Concentrations obtained from 80 children were analyzed routine therapeutic drug monitoring (TDM) between 2021 2022. We retrospectively reviewed clinical data these patients assessed at 3 months after treatment initiation. Trough concentration-to-dose ratio (C0 /Dose ratio)...
Abstract Objective To assess the efficacy and safety of perampanel (PER) as primary monotherapy in patients aged 4–18 years old with epilepsy. Methods A single‐center, prospective, observational study was conducted from October 2021 to 2023, evaluate PER monotherapy's initial therapy for pediatric Changes seizure frequency, safety, retention rate were observed at 3, 6, 9, 12 months after initiating monotherapy. Results total 124 children 4–15 (mean age = 8.25 ± 2.50 years) included Analysis...
This study assessed the relative cost-effectiveness of haloperidol decanoate (HD), a first-generation long-acting injectable (LAI) antipsychotic, and paliperidone palmitate (PP), second-generation LAI antipsychotic.A double-blind, randomized 18-month clinical trial conducted at 22 research sites in United States compared HD PP among 311 adults with schizophrenia or schizoaffective disorder who had been clinically as likely to benefit from an antipsychotic. Patients were randomly assigned...
Sirolimus (SRL) is a mammalian target of rapamycin (mTOR) inhibitor. The whole blood concentration SRL routinely monitored to tailor dosage and prevent toxicity. Currently, the enzyme multiplied immunoassay technique (EMIT) often applied perform therapeutic drug monitoring (TDM) SRL, but cross-reactivity with various metabolites great concern. A more specific method required, such as liquid chromatography–tandem mass spectrometry (LC-MS/MS). However, no study on comparison EMIT LC-MS/MS for...
To evaluate the effectiveness and safety of perampanel (PER) monotherapy (MT) or add-on therapy (AT) in Chinese children with epilepsy, as well to data from routine therapeutic drug monitoring (TDM) PER for these pediatric patients.
Lacosamide (LCM) is a newer anti-seizure medication (ASM) that was approved in China 2018, but its real-world clinical data and plasma concentrations Chinese children with epilepsy are very limited. Of note, the reference range for routine LCM therapeutic drug monitoring still unknown. The purpose of this study to investigate efficacy safety as monotherapy or an adjunctive treatment other ASMs evaluate potential factors affecting variable epilepsy.Children (<18 years) from March 2019...
Abstract Major depression affects the central nervous system and thereafter autonomic system, immune endocrine system. Na+/K+ ATPase, as a major mediator of cellular transmembrane ionic gradients, plays an important role in signal transduction. Three types ATPase α subunit isoforms (ATP1A1, ATP1A2, ATP1A3) are found brain but vary type cell level expression. It has been confirmed that reduced expression ATP1A2 ATP1A3 related to depressive disorder. However, there is no reported correlation...
<title>Abstract</title> <bold>PURPOSE: </bold>To investigate and understand the implementation of genetic testing for personalized medication (GTPM) in children’s hospitals mainland China. <bold>METHODS: </bold>A questionnaire survey was conducted on 50 pediatric from 31 provinces, municipalities, autonomous regions across China, statistical analysis recommendations were made. <bold>RESULTS: total questionnaires distributed 38 valid responses returned, giving a response rate 76.0%. All...
The widespread clinical use of lacosamide (LCM) has revealed significant individual differences in response, with various reported influencing factors. However, it remains unclear how genetic factors related to the disposition and response LCM, as well drug-drug interactions (DDIs), exert their influence on pediatric patients epilepsy.
: Sirolimus (SRL), a mammalian target of rapamycin inhibitor, has been widely used to treat patients with vascular anomalies (VAs). The objectives this study were summarize the routine blood SRL monitoring data for VAs children, investigate factors contributing variable concentrations and evaluate efficacy safety therapy.
The main challenges faced when using sirolimus in children with vascular anomalies (VAs) still include significant pharmacokinetic (PK) variability, uncertainty the target concentration range, as well inconsistencies initial dosing and frequency. aim of this study is to establish a new population (PPK) model for VAs guide individualized use sirolimus.